LEGEND BIOTECH CORP-ADR (LEGN) Forecast, Price Target & Analyst Ratings

NASDAQ:LEGN • US52490G1022

Current stock price

18.06 USD
-0.49 (-2.64%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LEGEND BIOTECH CORP-ADR (LEGN).

Forecast Snapshot

Consensus Price Target

Price Target
$65.80
+ 264.33% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.02
Revenue Estimate
315.06M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.40%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$65.80
Upside
+ 264.33%
From current price of $18.06 to mean target of $65.80, Based on 25 analyst forecasts
Low
$21.21
Median
$70.89
High
$95.55

Price Target Revisions

1 Month
-4.31%
3 Months
-12.22%

Price Target Summary

25 Wall Street analysts provided a forecast for the next 12 months for LEGN. The average price target is 65.8 USD. This implies a price increase of 264.33% is expected in the next year compared to the current price of 18.06.
The average price target has been revised downward by 12.22% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

LEGN Current Analyst RatingLEGN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

LEGN Historical Analyst RatingsLEGN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 10 20 30

Analyst Ratings Consensus

ChartMill Buy Consensus
82.40%
LEGN was analyzed by 25 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about LEGN.
In the previous month the buy percentage consensus was at a similar level.
LEGN was analyzed by 25 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-11RBC CapitalMaintains Outperform -> Outperform
2026-03-11Morgan StanleyMaintains Overweight -> Overweight
2026-02-04BarclaysMaintains Overweight -> Overweight
2026-01-22TD CowenDowngrade Buy -> Hold
2026-01-22HC Wainwright & Co.Maintains Buy -> Buy
2026-01-20RBC CapitalMaintains Outperform -> Outperform
2026-01-07OppenheimerInitiate Outperform
2025-12-17Cantor FitzgeraldMaintains Overweight -> Overweight
2025-12-12Morgan StanleyMaintains Overweight -> Overweight
2025-12-08UBSMaintains Buy -> Buy
2025-11-13Cantor FitzgeraldMaintains Overweight -> Overweight
2025-11-13RBC CapitalMaintains Outperform -> Outperform
2025-11-13BarclaysMaintains Overweight -> Overweight
2025-10-17HC Wainwright & Co.Maintains Buy -> Buy
2025-10-09JP MorganMaintains Overweight -> Overweight
2025-08-25JP MorganMaintains Overweight -> Overweight
2025-08-12RBC CapitalMaintains Outperform -> Outperform
2025-08-12Morgan StanleyMaintains Overweight -> Overweight
2025-07-17HC Wainwright & Co.Reiterate Buy -> Buy
2025-07-10Morgan StanleyMaintains Overweight -> Overweight
2025-07-08HC Wainwright & Co.Reiterate Buy -> Buy
2025-07-02UBSMaintains Buy -> Buy
2025-05-14Cantor FitzgeraldReiterate Overweight -> Overweight
2025-05-14Truist SecuritiesMaintains Buy -> Buy
2025-04-22RBC CapitalReiterate Outperform -> Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.02
Revenue Estimate
315.06M
Revenue Q2Q
61.53%
EPS Q2Q
97.00%
Number of Analysts
14

Next Earnings Revisions

Revenue (1 Month)
-5.70%
Revenue (3 Months)
-6.58%
EPS (1 Month)
-480.00%
EPS (3 Months)
-67.32%

Next Earnings Summary

LEGN is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.02 USD and the consensus revenue estimate is 315.06M USD.
The next earnings revenue estimate has been revised downward by 6.58% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
LEGN revenue by date.LEGN revenue by date.
285.143M
143.71%		627.241M
119.97%		1.029B
64.04%		1.505B
46.27%		1.938B
28.77%		2.605B
34.42%		2.453B
-5.83%		2.687B
9.54%		2.894B
7.70%		3.073B
6.19%		3.237B
5.34%
EBITDA
YoY % growth
LEGN ebitda by date.LEGN ebitda by date.
-507.515M
-15.42%		-281.789M
44.48%		-107.6M
61.82%		198.99M
284.93%		462.17M
132.26%		597.62M
29.31%		886.24M
48.29%		1.037B
17.01%		1.148B
10.70%		1.235B
7.58%		1.303B
5.51%
EBIT
YoY % growth
LEGN ebit by date.LEGN ebit by date.
-527.966M
-15.25%		-305.148M
42.20%		-136.5M
55.27%		161.95M
218.64%		439.67M
171.49%		954.7M
117.14%		1.021B
6.94%		1.205B
18.02%		1.323B
9.79%		1.411B
6.65%		1.489B
5.53%
Operating Margin
LEGN operating margin by date.LEGN operating margin by date.
-185.16%-48.65%-13.27%10.76%22.69%36.65%41.62%44.85%45.72%45.92%46.00%
EPS
YoY % growth
LEGN eps by date.LEGN eps by date.
-2.96
-100.97%		-0.95
67.91%		-1.60
-68.42%		0.34
121.03%		1.31
287.83%		1.50
14.98%		1.99
32.50%		3.36
68.77%		3.50
4.41%		3.86
10.19%		N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.02
97.00%		0.04
106.00%		0.10
147.52%		0.15
195.63%
Revenue
Q2Q % growth		315.06M
61.53%		365.1M
43.14%		391.55M
43.78%		429.61M
40.26%
EBITDA
Q2Q % growth		9.373M
120.62%		45.599M
521.12%		49.281M
285.83%		96.864M
945.14%
EBIT
Q2Q % growth		-4.617M
90.88%		36.92M
268.73%		37.935M
187.30%		91.512M
566.14%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
43.22%
EPS Next 5 Year
32.59%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
35.33%
Revenue Next 5 Year
20.65%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
78.48%
EBIT Next 5 Year
53.04%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

LEGEND BIOTECH CORP-ADR / LEGN Forecast FAQ

What is the price target for LEGN stock?

25 analysts have analysed LEGN and the average price target is 65.8 USD. This implies a price increase of 264.33% is expected in the next year compared to the current price of 18.06.

Can you provide the upcoming earnings date for LEGEND BIOTECH CORP-ADR?

LEGEND BIOTECH CORP-ADR (LEGN) will report earnings on 2026-05-11, before the market open.

Can you provide the consensus estimates for LEGEND BIOTECH CORP-ADR next earnings?

The consensus EPS estimate for the next earnings of LEGEND BIOTECH CORP-ADR (LEGN) is -0.02 USD and the consensus revenue estimate is 315.06M USD.

How do analysts rate LEGEND BIOTECH CORP-ADR (LEGN)?

The consensus rating for LEGEND BIOTECH CORP-ADR (LEGN) is 82.4 / 100 . This indicates that analysts generally have a positive outlook on the stock.